【一期一會】春風送暖，三月會議啟動中

Tips

hjc黄金城匯總整理了3月生物醫藥行業會議供參考交流。同時，我們將計劃參與海內外8場會議：

IVC2024第四屆核酸疫苗與創新疫苗研發工藝論壇

IVC2024第四屆核酸疫苗與創新疫苗研發工藝論壇將於2024年3月1-2日在上海盛大召開：80餘位專家學者，1000位行業同行邀您共襄盛會，2天3個會場全力打造疫苗盛宴。

2024（第四屆）類器官大會

為推動國際類器官領域的發展，促進研究人員深入交流合作，探討類器官研究領域的關鍵科學問題，2024（第四屆）類器官大會—類器官與新藥研發暨ISoOR 2024國際類器官高峰論壇將於2024年3月7-8日在中國上海雅居樂萬豪侯爵酒店召開。

第七屆成都生物醫藥創新者峰會

hjc黄金城首席科學官彭雙清教授將擔任論壇主持嘉賓，毒理研究部高級主任鄒漢軍博士將出席GLP1藥物開發論壇並發表主題演講。

第七屆成都生物醫藥創新者峰會將於2024年3月7-8日於成都舉辦，會議將涵蓋ADC，改良型新藥，小分子新藥，GLP-1藥物研發領域前沿動態，並聚焦最新臨床進展。旨在打破行業的信息壁壘，推動創新多元發展！屆時hjc黄金城商務團隊將在A01展位等候您的蒞臨。

第九屆細胞生物產業大會

細胞生物產業作為戰略性新興產業，近年來不斷獲得政策的支持和市場的青睞。2023更是細胞生物領域取得重大突破的一年，發改委對外發布的《產業結構調整指導目錄（2024年本）》，鼓勵細胞產業的發展，預示著我國細胞生物產業正在與全球前沿接軌。細胞生物產業在2023年的表現，為市場環境重振了信心，也為更多的研究立項帶來期待和轉機。

於此背景下，第九屆細胞生物產業大會暨第七屆中國生物醫藥創新合作大會將於2024年3月8-9日在深圳盛大開幕！本次大會由深圳市細胞治療技術協會、正和會展聯合組織，助力細胞生物產業創新發展，合作共贏！

SOT 63rd Annual Meeting and ToxExpo

More Science, More Networking, More Everything in 2024

Medicilon is excited to attend and exhibit at the conference. Dr. Haizhou Zhang, president of preclinical R&D unit at Medicilon, will be available at the booth. Dr. Zhang holds a PhD in Toxicology from Indiana University, USA. He is a pharmaceutical industry veteran with over 20 years of experience in the R&D of small and large molecule drugs.

Medicilon's state-of-the-art preclinical facilities hold full AAALAC accreditation. With advanced platforms and experienced scientists, Medicilon guarantees the utmost professionalism in drug efficacy and safety assessments services, adhering to global regulatory standards. Offering services from stand-alone preclinical studies to comprehensive IND-enabling packages, Medicilon provides flexible solutions to efficiently support biotech and pharmaceutical clients in reaching their developmental milestones.

14th World ADC London

Europe's Longest Standing & Definitive Antibody-Drug Conjugate Event！

Antibody-drug conjugates are an important class of therapeutics for the treatment of cancer. ADCs are coming of age with a remarkable surge in recent times, that has marked a turning point in their development.

In the formulation of ADC preclinical integrated research plan, Medicilon has in-depth communication with customers. The backbone of scientific research has combined the characteristics of each case with years of practical experience and technical accumulation, and carefully submitted high-quality experimental plans and results to customers. Medicilon started ADC non-clinical research in 2014. As of the end of 2023, We has successfully assisted in the clinical approval of 20+ ADC drugs by NMPA and/or FDA and has 30+ ADC projects under development.

2024 NEDMDG Spring Meeting

Recent interest in the delivery of therapeutics to the brain has dramatically increased with the advent of new ADCs and other targeted delivery vehicles for the treatment of dementias and glioblastoma. In addition, subcutaneous delivery has been found to be an effective mode of ADC delivery, but the bioavailability in humans has been difficult to predict. These two factors have driven an increasing interest in the human cell-based in vitro models for screening novel delivery methods to gain mechanistic insight into the factors that control either entry into the brain or systemic bioavailability of subcutaneously delivered drugs. In this presentation Dr. Roger Kamm will present the models specifically developed for both applications and the potential for iPS cell-derived systems. The benefits and current limitations of these models will also be addressed with the goal of stimulating an active discussion.

The Seminar is Sponsored by Medicilon.

IDC2024

從當前“創新”布局來看，內卷嚴重，靶點紮堆，同質化競爭激烈：內卷之中如何做到扶搖直上九萬裏而不被卷入旋渦，卻成了創新藥人當下最需要考慮的一點。

BIOCHINA2024(EBC)

hjc黄金城新分子類型專場將於3月16日在大會期間舉行，hjc黄金城毒理研究部副總裁曾憲成博士與毒理研究部高級主任鄒漢軍博士受邀出席並發表主題演講。

BIOCHINA2024第九屆易貿生物產業展覽(EBC)將於2024年3月14-16日在蘇州國際博覽中心ABCDEFG館召開。

BIOCHINA2024(EBC)全新起航，以“展覽-大會-活動”三大體係，規模30,000人、550家展商、500場學術報告。屆時hjc黄金城商務團隊將在C3館C060-C061展位等候您的蒞臨。

ACS Spring 2024

Many Flavors of Chemistry！

Founded in 1876 and chartered by the U.S. Congress, ACS is one of the world's largest scientific organizations with more than 200,000 individuals in its global community across 140 countries.

With the rapid development of the global pharmaceutical market and the division of labor in the industry, the process of drug discovery and development is becoming increasingly refined. This makes specialized outsourcing an important strategic choice for pharmaceutical companies. In the early stages, companies often use FTE models for the synthesis of structural fragments and candidate compounds to accelerate the drug screening process. Medicilon provides comprehensive chemistry research services covering all stages of your project requirements, and we offer cooperation through both FFS and FTE models.

2024hjc黄金城創新藥物產業生態合作大會

2004年，hjc黄金城成立。

回首廿載，hjc黄金城始終專注一站式臨床前研發服務平台建設，與中國創新藥企業攜手同行，共同見證行業的發展與蛻變。

2024年，為進一步推動中國新藥事業的高質量發展，hjc黄金城創新藥物產業生態合作大會將於2024年3月18日在上海舉行。500餘位行業精英共聚滬上，為創新藥物產業生態建言獻策，共同探索中國醫藥企業合作發展新機遇。

BIO-Europe Spring

Connecting the global biopharma community to elevate life science partnerships

BIO-Europe Spring, the premier springtime partnering event, brings together over 3,700 attendees from 2,000+ companies to engage in 20,000 one-to-one meetings.

Medicilon provides comprehensive one-stop R&D services for pharmaceutical enterprises and scientific research institutions around the world. Based on the key requirements of drug R&D, we focus on meeting the demand for innovation and development. With our experience in serving domestic and foreign biomedical industries, we have built an integrated platform covering key technologies in drug discovery, pharmaceutical research, and preclinical research, to provide a comprehensive preclinical R&D service for the global biomedical industry. By the end of 2023, we have served more than 2000 clients globally with more than 300 INDs approved in China and more than 80 INDs approved overseas.

SIT 2024第六屆小分子藥物創新與合作大會

本屆大會內容將聚焦小分子藥物的創新開發、立項策略、生產與MAH、轉化醫學、合作共贏、PROTAC、共價抑製劑、PPI、變構抑製劑、多肽偶聯藥物、多肽減重藥物、 AI與CADD助力新藥開發及其他新技術等，跨越小分子藥物研發的熱點領域，一覽當下化學創新藥研發新動向，致力於打破行業的封閉循環，破除行業內卷，助推創新多元發展!一切盡在小分子藥物的年度產業大會!

SABPA Event

8th Annual Frontiers in Therapeutics and Diagnostics (FTD) Forum

SABPA FTD annually brings together the latest in groundbreaking research, cutting-edge drugs, and industry trends within the biopharma sector. The event's broad spectrum of topics provides a platform to engage in vibrant discussions and valuable networking opportunities. The forthcoming 8th FTD Conference is set to shine a spotlight on three revolutionary domains in the field of metabolism disease and oncology: GLP-1, ADC, and Minimal Residual Disease (MRD), each representing the forefront of innovations in therapeutics and diagnostics.

2024生物藥創新與質量大會

生物藥是目前最具投資價值的醫藥細分領域，在全球在研藥物整體中的比例逐年上升。伴隨國家各類醫藥政策的扶持和資本的孵化，中國生物醫藥創新迎來了新的曆史機遇。

生物醫藥研發與創新相關技術的進步是生物醫藥產業發展的基礎。為推動生物醫藥產業發展，更好地促進生物技術產學研交流，由中國食藥促進會檢驗檢定分會、四川省生物化學與分子生物學學會、四川省藥學會藥物分析專業委員會和四川省藥學會生物藥物專業委員會主辦，藥檢匯聯合主辦，由杭州奇易科技有限公司承辦的“BIQC2024生物藥創新與質量大會”將於2024年3月在成都舉行。大會以“創新引領高質量發展”為主題，搭建合作交流平台，聚焦國家發改委“十四五”生物經濟發展規劃，探討新時代變革中生物醫藥產業發展的新思路、新路徑。圍繞mRNA疫苗、多肽藥物、抗體偶聯等前沿生物技術、生物藥研發創新與質量控製展開深入交流和研討。

第二屆中國生物藥分析與質量峰會

隨著生物藥技術的不斷發展，藥物的類型越來越多，我國的生物藥研發與生產也進入到一個快速增長的時期。

生物藥的分子量大、空間結構嚴格、修飾形式和變異體多樣等特點，給藥物分析與質量控製帶來了巨大挑戰。血清、血漿、唾液、尿液和組織等生物基質中藥物濃度測定是藥物研發的重要環節，科學的生物分析方法對於藥物藥代動力學、毒代動力學、生物等效性等藥物的臨床前研究提供依據。理化、雜質、生物學活性、免疫學特性及相關的表征研究等非常複雜，科學的質量管理與控製體係是生物藥研發及生產重點關注與探討的方向。生物藥分析與質量峰會BioAQ是藥物分析、質量及監管方麵重要的交流平台，致力於促進生物醫藥行業產、學、研技術交流與合作。峰會圍繞當下生物藥發展趨勢和監管要求，對單抗、雙/多抗、重組/融合蛋白、細胞治療、基因治療、核酸藥物等的生物分析方法與質量控製進行分享和深入探討。

marketing@yakkaa.com
微信或郵件聯係我們